LINCOLN vs PFIZER: Stock Comparison

Lincoln Pharmaceuticals Limited vs Pfizer Limited

Live data: 22 July 2026, 2:53 PM IST • Source: NSE and company filings

Pfizer Limited is the larger company by market capitalisation. Lincoln Pharmaceuticals Limited shows a lower P/E and faster revenue growth, while Pfizer Limited shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lincoln Pharmaceuticals Limited and Pfizer Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LINCOLN is more favourable on 5 of 11 scored metrics and PFIZER on 6These counts are context-free and are not an overall rating.

Lincoln Pharmaceuticals Limited

Key Differences

Market Cap

PFIZER is the larger company

₹21,242 Cr vs ₹1,166 Cr

P/E Ratio

LINCOLN has a lower P/E

13.64x vs 29.12x

P/B Ratio

LINCOLN has a lower P/B

1.58x vs 5.01x

EPS

PFIZER has higher earnings per share

₹157.72 vs ₹43.87

Dividend Yield

PFIZER has a higher dividend yield

2.83% vs 0.29%

Revenue Growth (TTM YoY)

LINCOLN has faster revenue growth

11.4% vs 6.3%

EPS Growth (TTM YoY)

LINCOLN has faster EPS growth

0.6% vs -39.6%

ROE

PFIZER has a higher ROE

19.8% vs 12.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

Metric	LINCOLN	PFIZER
Sector	Healthcare	Healthcare
Industry	Pharmaceuticals	Pharmaceuticals

Price

Metric	LINCOLN	PFIZER
Live Price	₹581.4	₹4,653.7
Day Change	-2.86%	1.31%
Volume	26,430	18,014
52-Week High	₹770	₹5,873.5
52-Week Low	₹440	₹4,360.1
Distance from 52W High	-24.49%	-20.77%

Valuation

Metric	LINCOLN	PFIZER
Market Cap	₹1,166 Cr	₹21,242 Cr
P/E Ratio	13.64x	29.12x
P/B Ratio	1.58x	5.01x
EPS	₹43.87	₹157.72
Book Value	₹378.34	₹918.74
Dividend Yield	0.29%	2.83%

Growth

Metric	LINCOLN	PFIZER
Revenue Growth (TTM YoY)	11.4%	6.3%
EPS Growth (TTM YoY)	0.6%	-39.6%
Qtr Sales Growth	11.4%	—
Qtr Profit Growth	0.43%	—

Profitability & Leverage

Metric	LINCOLN	PFIZER
ROE	12.3%	19.8%
ROCE	16.3%	27.2%
Net Margin	13.1%	28.67%
Operating Margin	14.6%	-12.1%
Debt to Equity	0.01x	0x

Shareholding

As of Jun 2026 • change vs previous quarter

Metric	LINCOLN	PFIZER
Promoter Holding	49.78%	63.92%
FII Holding	4.6%▼ 0.59 pp	1.65%▼ 1.16 pp
DII Holding	0.27%▼ 0.82 pp	17.8%▲ 0.91 pp
Public Holding	45.36%▲ 1.42 pp	16.63%▲ 0.26 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lincoln Pharmaceuticals Limited and Pfizer Limited.

Related Comparisons

Infosys vs TCS HDFC Bank vs ICICI Bank Axis Bank vs Kotak Mahindra Bank HCL Technologies vs Wipro Hindustan Unilever vs ITC Maruti Suzuki vs Tata Motors

Browse all stock comparisons →

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.